Recombinant Human B7-H2 Isoform 3 Fc Avi-tag Protein, CF

When Recombinant Human ICOS Fc Chimera (Catalog # 169-CS) is immobilized at 10 μg/mL, 100 μL/well, the concentration of Biotinylated Recombinant B7-H2 Isoform 3 Fc Chimera Avi-tag (Catalog # AVI10028) that produces 50% of the optimal binding response is approximately 10-50 μg/mL.

2 μg/lane of Biotinylated Recombinant Human B7-H2 Isoform 3 Fc Chimera Avi-tag (Catalog # AVI10028) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 61-70 kDa and 120-140 kDa.

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human B7-H2 Isoform 3 Fc Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Human ICOS Fc Chimera (Catalog # 169-CS) is immobilized at 10 μg/mL, 100 μL/well, the concentration of Biotinylated Recombinant B7-H2 Isoform 3 Fc Chimera Avi-tag (Catalog # AVI10028) that produces 50% of the optimal binding response is approximately 10-50 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human B7-H2 protein
  

  Human B7-H2 (Ala19-Thr139) Accession # NP_001269980.1	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: NP_001269980.1
• N-terminal Sequence: Ala19
• Structure / Form: Disulfide-linked homodimer, biotinylated via Avi-tag
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <1.0 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 42 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 61-70 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 400 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human B7-H2 Isoform 3 Fc Avi-tag Protein, CF

• B7H2
• B7-H2
• B7H2B7 homolog 2
• B7-H2B7-related protein 1
• B7RP-1
• B7RP1B7-like protein Gl50
• B7RP-1LICOS
• CD275 antigen
• CD275
• GL50
• GL50transmembrane protein B7-H2 ICOS ligand
• ICOSL
• ICOS-L
• ICOSLG
• inducible T-cell co-stimulator ligand
• KIAA0653ICOS ligand

Background

B7-H2, also known as B7-related protein (B7RP1), ICOS Ligand, and CD275, is an approximately 60 kDa transmembrane glycoprotein in the B7 family of immune regulatory molecules (1). Mature human B7-H2 consists of a 238 amino acid (aa) extracellular domain (ECD) with two immunoglobulin-like (Ig-like) domains, a 21 aa transmembrane segment, and a 25 aa cytoplasmic domain (2, 3). Within the ECD, human B7-H2 shares 50% and 54% aa sequence identity with mouse and rat B7‑H2, respectively. Alternative splicing generates a long isoform (Isoform 2),  which carries a 10 aa substitution for the C-terminal 3 residues, and a short isoform (Isoform 3; this product), which lacks the first Ig-like domain (aa 18 - 134 is missing) . B7-H2 is expressed on antigen presenting cells such as B cells, macrophages, monocytes, and dendritic cells (2-6). It binds to ICOS on activated T cells, leading to both positive and negative effects on immune responses including its own down-regulation (2, 4, 7). Mouse and human B7-H2 exhibit cross-species binding to ICOS (3, 6). The B7-H2 interaction with ICOS is costimulatory for T cell proliferation as well as the development of B cells, plasma cells, follicular helper T cells (T^FH) and germinal centers (2-4, 8, 9). In human but not in mouse, B7-H2 additionally binds to CD28 and CTLA4, and its interaction with CD28 can costimulate both human and mouse naïve T cells and regulatory T cells (Treg) (6). B7-H2 contributes to the development of allergic asthma by enhancing Th2 biased immune responses, limiting Th17 responses, and promoting eosinophilic infiltration into the lung (8, 10, 11). Its activation of ICOS on Treg limits pulmonary inflammation and airway hyperresponsiveness, promotes the development of inhalational tolerance, and impairs anti-tumor immunity (5, 12, 13). In contrast, its ligation of ICOS on T^FH cells can increase the severity of autoimmune symptoms (9). A soluble form of human B7-H2 is elevated in the circulation of patients with active systemic lupus erythematosus (14). In the thyroid, B7-H2 is up-regulated on thyrocytes during inflammation and promotes their proliferation and production of thryoid hormones (15).

1. Bour-Jordan, H. et al. (2011) Immunol. Rev. 241:180.
2. Wang, S. et al. (2000) Blood 96:2808.
3. Yoshinaga, S.K. et al. (2000) Int. Immunol. 12:1439.
4. Yoshinaga, S.K. et al. (1999) Nature 402:827.
5. Faget, J. et al. (2012) Cancer Res. 72:6130.
6. Yao, S. et al. (2011) Immunity 32:729.
7. Watanabe, M. et al. (2008) J. Immunol. 180:5222.
8. Wong, S.-C. et al. (2003) Blood 102:1381.
9. Hu, Y.-L. et al. (2009) J. Immunol. 182:1421.
10. Kadkhoda, K. et al. (2010) J. Immunol. 184:3780.
11. Kadkhoda, K. et al. (2011) Int. Immunol. 23:239.
12. Gajewska, B.U. et al. (2005) J. Immunol. 174:3000.
13. Akbari, O. et al. (2002) Nat. Med. 8:1024.
14. Her, M. et al. (2009) Lupus 18:501.
15. Wang, F. et al. (2012) J. Clin. Immunol. 32:1253.

Bioinformatics

• Uniprot:
  • NP_001269980.1()